Close button
Enquiry IconContact Us
Logo
  • Choose License Type

Global Dual Specificity Protein Kinase TTK Inhibitors Market, by Product Type (BAY 1217389, BOS-172722, CFI-402257, S 81694, and Others), by Application (Non-hematologic Malignancies, Breast Cancer, Prostate Cancer, Pancreatic Ductal Adenocarcinoma, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 51.92 Mn in 2025 and is expected to exhibit a CAGR of 29.4% during the forecast period (2026-2028), as highlighted in a new report published by Coherent Market Insights.

The increasing adoption of acquisition strategies by key players is expected to propel the global dual specificity protein kinase TTK inhibitors market growth over the forecast period. For instance, in June 2020, Servier Laboratories, an international pharmaceutical company, announced its acquisition of Symphogen A/S. Symphogen is a subsidiary of Servier and functions as the antibody Center of Excellence of Servier in different therapeutic areas, primarily oncology and immune-oncology.

Global Dual Specificity Protein kinase TTK Inhibitors Market – Impact of Coronavirus (COVID-19) Pandemic

While the healthcare industry continues to focus on the development of COVID-19 vaccines and therapies, the COVID-19 crisis has a significant impact on clinical trials in many therapy areas such as oncology, cardiovascular, dermatology, and others. Major regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued several guidelines and measures to ensure the integrity of trials that attempt to guarantee the rights, safety, and well-being of patients and healthcare staff during the pandemic. However, maintaining and keeping clinical trials on track has been extremely difficult.

The COVID-19 pandemic has clearly changed the world, and there are numerous consequences for conducting clinical trial. These include concerns about patients’ safety and reallocation, and also the lack of staff or resources to house these patients. The supply chain has also been disrupted due to lockdowns and closed borders, affecting the shipping of clinical trial samples to central laboratories. Furthermore, the pandemic resulted in a reduction and/or delay in patient enrolment and extended duration of trials because the study is either slowed down or interrupted during the recruitment. Moreover, the lockdowns prevented patients from entering hospitals and carrying out the trials. As a result, there is a need to limit patient risk and support participation in clinical trials. Innovation, flexibility, and the proper use of existing technologies are essential for adapting to this new paradigm.

Browse 26 Market Data Tables and 26 Figures spread through 141 Pages and in-depth TOC on ‘Global Dual Specificity Protein Kinase TTK Inhibitors Market’ - Forecast to 2028, Global Dual Specificity Protein Kinase TTK Inhibitors Market, by Product Type (BAY 1217389, BOS-172722, CFI-402257, S 81694, and Others), by Application (Non-hematologic Malignancies, Breast Cancer, Prostate Cancer, Pancreatic Ductal Adenocarcinoma, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Dual Specificity Protein Kinase TTK Inhibitors Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/dual-specificity-protein-kinase-ttk-market-2373

The increasing prevalence of non-hematologic cancer is expected to drive this application segment growth over the forecast period. According to the statistics provided by the American Cancer Society, in 2021, there were around 235,760 new cases of lung cancer (119,100 in men and 116,660 in women) in the U.S., which caused around 131,880 deaths.

Key Takeaways of the Global Dual Specificity Protein Kinase TTK Inhibitors Market:

  • The global dual specificity protein kinase TTK inhibitors market is expected to exhibit a CAGR of 29.4% during the forecast period due to increasing agreements among the key players. For instance, in August 2017, Boston Pharmaceuticals, a company that acquires and transforms innovative molecules into differentiated medicines to improve patients’ lives, and Daiichi Sankyo Company, Limited, a global pharmaceutical company, announced a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS- 5010. It is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor.
  • On the basis of application, the breast cancer segment is estimated to account for the largest share in the global dual specificity protein kinase TTK inhibitors market in 2021. Increasing research activities on TTK inhibitors as a treatment option for breast cancer is expected to drive the segment growth over the forecast period. For instance, an article published in Oncogenesis journal in September 2018 revealed the novel role and signaling pathway of TTK in regulating epithelial-to-mesenchymal transition (EMT) of triple negative (TN) breast cancer cells through TGF-β and KLF5 signaling. It highlighted targetable signaling pathways for TTK inhibitors in aggressive breast cancer which represents TTK as an attractive therapeutic target for breast cancer.
  • Among regions, North America is estimated to account for the largest share in the global dual specificity protein kinase TTK inhibitors market in 2021, owing to the increasing prevalence of cancer in the region. According to an article published by the National Cancer Institute, in 2021, around 1.9 million people will be diagnosed with cancer in the U.S in 2021. According to the same source, an estimated 2,650 men and 281,550 women will be diagnosed with breast cancer, which makes breast cancer the most common diagnosis in cancer.
  • Major players operating in the global dual specificity protein kinase TTK inhibitors market include Bayer AG, Pfizer Inc., Boston Pharmaceuticals, Nerviano Medical Sciences S.R.L (Part of NMS group), and Servier Laboratories
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.